467 filings
EFFECT
NRBO
NeuroBo Pharmaceuticals Inc
24 Apr 24
Notice of effectiveness
12:15am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
16 Apr 24
Other Events
4:30pm
S-3
NRBO
NeuroBo Pharmaceuticals Inc
Shelf registration
12 Apr 24
4:06pm
8-K
NRBO
NeuroBo Pharmaceuticals Inc
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
qx2mojo6jwte5weubqzt
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
iiz9y 2jc
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
4
th2e0jkc0mmcvg
4 Mar 24
NeuroBo Pharmaceuticals / Marshall H Woodworth ownership change
9:20pm
8-K
wx9tvkzcikn5awpi5uh
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
v4dmoe3hf7r5nnqo
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
4oqirze8e
14 Feb 24
Other Events
8:52am
8-K
glhtce cau1b5
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
8xfnq
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
1j9u2g3cv9clyx
9 Jan 24
Other Events
8:45am
8-K
72cyls4v3y2h5
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am
8-K
fgw1u
19 Dec 23
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
9:03am
8-K
ukto 8psi
7 Dec 23
Regulation FD Disclosure
9:20am
4
h5k880k79m2y vq9
4 Dec 23
NeuroBo Pharmaceuticals / James Patrick Tursi ownership change
5:12pm